General Information of the Compound
| Compound ID |
CP0035974
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
Sulfamate 7
Show/Hide
|
||||||||||||||||||
| Synonyms |
2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-(beta)-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate
5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, beta
Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate
Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI);Beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate
Cilag brandof topiramate
Epitoma
Epitomax
Janssen brand of topiramate
KS-1122
KW-6485
McN 4853
McN-4853
Ortho brand of topiramate
RWJ 17021
RWJ-17021
RWJ-17021-000
TOR
Tipiramate
Tipiramate [French]
Tipiramato
Tipiramato [Spanish]
Topamac
Topamax
Topamax (TN)
Topamax Sprinkle
Topamax, Topiramate
Topimax
Topina
Topiramate
Topiramate (JAN/USAN/INN)
Topiramate (TPM)
Topiramate / Placebo
Topiramate [USAN:BAN:INN]
Topiramate tablet
Topiramato
Topiramato [INN-Spanish]
Topiramatum
Topiramatum [INN-Latin]
Topiramatum [Latin]
Topiramic acid
Topomax
USL-255
[(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C12H21NO8S
|
||||||||||||||||||
| Molecular Weight |
339.366
|
||||||||||||||||||
| Canonical SMILES |
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1
Show/Hide
|
||||||||||||||||||
| InChIKey |
KJADKKWYZYXHBB-XBWDGYHZSA-N
|
||||||||||||||||||
| CAS |
97240-79-4
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Clinical Information about the Compound